Nuclear Medicine Radioisotopes Market Global Report 2026

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.89 billion in 2025 to $9.64 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the widespread utilization of technetium-99m in diagnostic imaging, increasing adoption of nuclear cardiology procedures, rising prevalence of cancer and thyroid disorders, expansion of hospital-based nuclear medicine departments, and early clinical success of radioisotope-based therapies.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to rising demand for personalized cancer treatment, increasing use of lutetium-177 and actinium-225 therapies, expansion of positron emission tomography imaging infrastructure, growing investments in cyclotron and reactor facilities, and rising adoption of nuclear medicine in emerging economies. Major trends in the forecast period include increasing adoption of theranostics in oncology care, growing demand for positron emission tomography and single-photon emission computed tomography imaging procedures, increased use of targeted alpha and beta emitters, expansion of nuclear medicine applications in cardiology and neurology, and strengthening focus on domestic radioisotope production.

The increased government funding for nuclear energy is expected to propel the growth of the nuclear fusion market going forward. Nuclear energy refers to energy generated by splitting atoms in a reactor to produce heat, which is then used to create steam, operate a turbine, and generate electricity. Several governments in developed countries are providing funding for nuclear reactor development, which is increasing demand for the nuclear fusion market. For instance, in January 2024, the Sunak Conservative government in the UK announced a comprehensive plan to quadruple the country's nuclear capacity by 2050, with a target of reaching 24 gigawatts (GW). This initiative forms part of the Civil Nuclear Roadmap, which outlines strategies to improve energy independence and security, reduce electricity costs, and support employment in the nuclear sector. The government planned to invest up to £300 ($389.5) million in domestic production of high-assay low-enriched uranium (HALEU) and committed to developing new large-scale reactors and small modular reactors (SMRs) as part of the country’s nuclear expansion. Therefore, increased government funding for nuclear energy is driving the growth of the nuclear fusion market.

Key companies operating in the nuclear medicine radioisotopes market are focusing on developing innovative solutions such as next-generation theranostic radiopharmaceuticals to enhance precision imaging and targeted treatment. Next-generation theranostic radiopharmaceuticals are advanced radioactive agents designed to both detect and precisely treat diseases by targeting specific cells in the body with high accuracy. For example, in November 2025, the University of California, a US-based research university, launched a completely independent Department of Nuclear Medicine & Theranostics rather than keeping nuclear medicine under a broader radiology umbrella. This new department aims to accelerate the integration of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and drive innovations in theranostic treatments.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals sought to reinforce its nuclear medicine capabilities, streamline production processes, and expand its portfolio of diagnostic and therapeutic radiopharmaceuticals. ARTMS is a Canada-based company that develops innovative radioisotope technologies and operates in the nuclear medicine radioisotope sector.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation.

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.